Atreca Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 134 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $2.23 |
|---|---|
| 52-week range | $1.51 - $9.77 |
| 50-day moving average | $1.87 |
| 200-day moving average | $3.26 |
| Wall St. target price | $14.89 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.91 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.23 from 2022-07-05
| 1 week (2022-06-29) | 21.86% |
|---|---|
| 1 month (2022-06-02) | 42.95% |
| 3 months (2022-04-05) | -28.06% |
| 6 months (2022-01-02) | N/A |
| 1 year (2021-07-06) | -74.69% |
|---|---|
| 2 years (2020-07-06) | -90.38% |
| 3 years (2019-07-05) | 16.22 |
| 5 years (2017-07-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -28.86% |
| Return on equity TTM | -60.37% |
| Profit margin | 0% |
| Book value | $3.57 |
| Market capitalisation | $69.1 million |
TTM: trailing 12 months
We're not expecting Atreca to pay a dividend over the next 12 months.
Atreca's shares were split on a 1:6 basis on 6 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.
Over the last 12 months, Atreca's shares have ranged in value from as little as $1.51 up to $9.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atreca's is 0.7785. This would suggest that Atreca's shares are less volatile than average (for this exchange).
Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.